Hemophilia & Thrombosis Research Society Receives Funding from ZLB Behring To Support Mentored Research Awards
$300,000 in Grants Will Advance Bleeding Disorder Research
MILWAUKEE, WI — 11 October 2006
The Hemophilia & Thrombosis Research Society (HTRS) has received an unrestricted educational grant from ZLB Behring to help financially support the Society’s Mentored Research Awards. The awards are given to physician-investigators pursuing basic, clinical, and or epidemiologic research in the areas of hemostasis and thrombosis. ZLB Behring will provide $300,000 to HTRS over the next two years to help fund research by physicians pursuing careers in hemostasis, specifically. Each year, ZLB Behring will fund two awards at $75,000 per awardee per year.
"HTRS is dedicated to promoting the implementation of clinical research that will improve the care of persons affected with disorders of hemostasis and thrombosis, in particular those persons with hemophilia," said Leonard A. Valentino, M.D. President of HTRS and Director of the Hemophilia and Thrombophilia Center at Rush University Medical Center in Chicago. "The generosity of organizations such as ZLB Behring allows us to meet our goals."
"ZLB Behring is committed to advancing the care and improving the quality of life for individuals with bleeding disorders such as hemophilia and von Willebrand disease," said Garrett E. Bergman, M.D., Senior Director of U.S. Medical Affairs at ZLB Behring. "We are pleased to support the next generation of clinicians dedicated to this field by funding these Research Awards."
Awardees are medical doctors who must be within five years of completing their core clinical rotations for hematology subspecialty training. Awardees select a mentor who is an established researcher and agrees to supervise them during the funding period.
About the Hemophilia & Thrombosis Research Society
The mission of the HTRS is to promote the care of persons with hemophilia and other bleeding or clotting disorders through collaborative research and postgraduate education. The Society was incorporated in 1994, and has grown to include a membership of clinicians, scientists, health care providers, and industry representatives whose focus is hemostasis and thrombosis. For more information about the organization, please visit www.htrs.org.
About ZLB Behring
ZLB Behring LLC is a global leader in the plasma protein biotherapeutics industry. Dedicated to improving the quality of life for patients throughout the world, ZLB Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services. The company’s broad portfolio of life-saving therapeutics are used in the treatment of individuals with hemophilia and other bleeding disorders, immune deficiency disorders and inherited emphysema; the prevention of hemolytic diseases for the newborn; cardiac surgery patients; and shock and burn victims. Additionally, ZLB Behring operates one of the world’s largest, fully-owned plasma collection networks. ZLB Behring is a subsidiary of CSL Limited, a biopharmaceutical company, which operates worldwide from its headquarters in Melbourne, Australia. For more information about the company, please visit www.zlbbehring.com.
Brian Thompson, MCS Public Relations
(800) 477-9626 ext. 23